Cholesterol

Cholesterol

SCHEMBL1369602

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C.O=C(O)O

nearest known ligand 0.93

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Cholesterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OSBP P22059 5/20 0.93
RORC P51449 3/20 0.93
OSBP2 Q969R2 2/20 0.93
USP2 O75604 1/20 0.93
LMNA P02545 1/20 0.93
ABCB1 P08183 1/20 0.93
CYP46A1 Q9Y6A2 1/20 0.93
NR1H3 Q13133 8/20 0.79
EPHA2 P29317 1/20 0.79
GRIN1 Q05586 4/20 0.79
GRIN2A Q12879 4/20 0.79
NPC1L1 Q9UHC9 2/20 0.75
CRYAB P02511 1/20 0.75
HMGCR P04035 1/20 0.75
ITGB3 P05106 1/20 0.75
ITGAV P06756 1/20 0.75
SREBF2 Q12772 1/20 0.75
GRIN2B Q13224 3/20 0.74
POLA1 P09884 1/20 0.73
DHCR24 Q15392 2/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cholesterol SCHEMBL27668883 1.00 OSBP (0.93) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL29502101 1.00 OSBP (0.93) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL27608874 0.99 OSBP (0.91) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL31090041 0.97 OSBP (0.91) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL25657 0.97 OSBP (0.91) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL27420666 0.97 OSBP (0.91) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL30101141 0.97 OSBP (0.91) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL29491181 0.97 OSBP (0.91) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL2460866 0.97 OSBP (0.98) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL27893800 0.97 OSBP (0.98) OSBPRORCOSBP2USP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265123-A1 PEPTIDES AND FORMULATIONS FOR CANCER TREATMENT PEPTINOVO BIOPHARMA INC. 2023-08-24 US claimed
EP-4196166-A2 PEPTIDES AND FORMULATIONS FOR CANCER TREATMENT Peptinovo Biopharma Inc. (US) 2023-06-21 EP claimed
CN-111568631-B Cooling paste with temperature indication function and preparation method thereof 武汉中科先进材料科技有限公司 2022-08-05 CN claimed
CN-108350036-B Formulations for improving the efficacy of hydrophobic drugs 佩蒂诺沃生物制药有限责任公司 2022-04-08 CN claimed
CN-122029108-A Temporary containment barrier and related methods 纽森斯IP公司 2026-05-12 CN disclosed
CN-120040306-A Diamines 日产化学株式会社 2025-05-27 CN disclosed
CN-120004765-A Liquid crystal aligning agent, liquid crystal alignment film, liquid crystal display element, and diamine 日产化学株式会社 2025-05-16 CN disclosed
CN-113711117-B Liquid crystal aligning agent, liquid crystal alignment film, liquid crystal display element, and diamine 日产化学株式会社 2025-02-21 CN disclosed
CN-115136068-B Liquid crystal aligning agent, liquid crystal alignment film, liquid crystal display element, and diamine 日产化学株式会社 2025-02-14 CN disclosed
CN-119236187-A Polymer encapsulated drug particles 吉益医疗公司 2025-01-03 CN disclosed
CN-113396359-B Liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal display element using same 日产化学株式会社 2024-12-17 CN disclosed
CN-115461096-B Polymer encapsulated drug particles 吉益医疗公司 2024-09-13 CN disclosed
US-20020132007-A1 Sustainded-release composition including amorphous polymer UNIVERSITY TECHNOLOGY CORPORATION 2002-09-19 US disclosed
US-20020032166-A1 Biocompatible cationic detergents and uses therefor UNIVERSITY TECHNOLOGY CORPORATION 2002-03-14 US disclosed
EP-1073419-A2 SUSTAINED-RELEASE COMPOSITION INCLUDING AMORPHOUS POLYMER University Technology Corporation (US) 2001-02-07 EP disclosed
WO-1999047543-A2 SUSTAINED-RELEASE COMPOSITION INCLUDING AMORPHOUS POLYMER UNIVERSITY TECHNOLOGY CORPORATION (US) 1999-09-23 WO disclosed
WO-1998010649-A9 BIOCOMPATIBLE CATIONIC DETERGENTS AND USES THEREFOR 1998-05-22 WO disclosed
WO-1998010649-A1 BIOCOMPATIBLE CATIONIC DETERGENTS AND USES THEREFOR UNIVERSITY TECHNOLOGY CORPORATION (US) 1998-03-19 WO disclosed
US-4035060-A Electro-optic device DAINIPPON PRINTING CO., LTD (JA) 1977-07-12 US disclosed
US-3944330-A Electro-optic device DAINIPPON PRINTING CO., LTD. (JA) 1976-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265123-A1 PEPTIDES AND FORMULATIONS FOR CANCER TREATMENT PHOSPHO1, NGLY1, ANXA11 OSBP 301/4885RORC 4350/4885OSBP2 218/4885
US-20020132007-A1 Sustainded-release composition including amorphous polymer CHERP, ATP2A1, ATP2A3 OSBP 1596/4885RORC 3737/4885OSBP2 799/4885
US-20020032166-A1 Biocompatible cationic detergents and uses therefor HASPIN, WASF2, DSC1 OSBP 590/4885RORC 3961/4885OSBP2 808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.